NCT05036434 2026-01-23
ACCOMPLISH
National Cancer Center, Korea
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT04790474 2025-07-24
IPoD-790
Tel-Aviv Sourasky Medical Center
Phase 2 Active not recruiting
NCT04864067 2025-07-01
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Active not recruiting
NCT06394661 2025-06-23
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT05000710 2024-12-05
CORAL-Lung
Sheba Medical Center
Phase 2 Active not recruiting
NCT01686126 2024-08-28
feMMe
Queensland Centre for Gynaecological Cancer
Phase 2 Active not recruiting
NCT06531447 2024-08-01
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients
The National Center of Oncology, Azerbaijan
Phase 2 Active not recruiting
NCT03950271 2024-02-28
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT03756298 2023-11-09
Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Center, Korea
Phase 2 Active not recruiting